The global viral inactivation market accounted for USD 0.641 billion in 2023 and is expected to reach at USD 2.33 billion by 2034 with a CAGR of 12.46% during the forecast period 2024-2034. Global pandemics and public health emergencies, strict regulatory requirements, technological advancements, rising adoption of single-use systems, and rising incidence of viral infections will propel market expansion.
Viral clearance processes are now more effective, efficient, and scalable thanks to ongoing developments in viral inactivation technologies, including the creation of new chemical agents, cutting-edge filtration techniques, and sophisticated irradiation methods. Through the provision of safer, more affordable, and more dependable viral inactivation solutions to biopharmaceutical manufacturers, these technological advancements propel market expansion. For instance, in January 2024, Merck KGaA declared that it had completed the acquisition of Amnis Therapeutics, a biopharmaceutical company in the clinical stage that specializes in creating innovative treatments for autoimmune disorders.
By the method, the solvent/detergent inactivation segment accounted for the highest revenue-grossing segment in the global viral inactivation market in 2023 owing to the increasing demand for plasma-derived products and blood safety measures, stringent regulatory requirements, and proven efficacy in viral clearance. For instance, in February 2023, Charles River Laboratories International, Inc. announced the expansion of its viral clearance and safety testing services by establishing a new facility in Shanghai, China, to meet the growing demand for biologics development in the Asia-Pacific region. Additionally, the other methods segment is predicted to grow at the fastest CAGR during the forecast period owing to the development of novel viral inactivation technologies, increasing focus on enhancing biopharmaceutical manufacturing efficiency, and rising investments in research and development for advanced viral clearance solutions.
By product, the kits and reagents segment accounted for the highest revenue-grossing segment in the global viral inactivation market in 2023 owing to the growing demand for ready-to-use solutions, expanding biopharmaceutical manufacturing activities, and the convenience offered by pre-packaged viral inactivation kits and reagents. For instance, Parker Hannifin Corporation unveiled a new range of viral filtration products in November 2023 with the goal of improving the effectiveness and security of biopharmaceutical manufacturing procedures. Additionally, the viral inactivation systems and accessories segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of automated viral clearance processes, advancements in system integration and compatibility, and the need for scalable solutions in biopharmaceutical manufacturing.
By application, the vaccines and therapeutics segment accounted for the highest revenue-grossing segment in the global viral inactivation market in 2023 owing to the growing demand for safe and effective vaccines, expanding therapeutic development pipelines, and stringent regulatory requirements for viral safety in biopharmaceutical products. For instance, Thermo Fisher Scientific developed the non-hazardous InhibiSURE Viral Inactivation Medium formula in March 2022. a novel viral transport medium that stabilizes viral RNA for use in in vitro diagnostic testing techniques and facilitates the rapid transfer and inactivation of the SARS-CoV-2 virus. Additionally, the cellular and gene therapy products segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing investments in regenerative medicine, advancements in cellular and gene therapy research, and rising adoption of viral inactivation technologies to ensure product safety and efficacy.
By end-user, the pharmaceutical and biotechnology companies segment accounted for the highest revenue-grossing segment in the global viral inactivation market in 2023 owing to the expanding biopharmaceutical pipelines, stringent regulatory compliance requirements, and increasing outsourcing of viral clearance processes by pharmaceutical and biotechnology firms. For instance, Danaher Corporation expanded its portfolio of life sciences and diagnostics solutions in October 2023 when it completed the acquisition of Bio-Rad Laboratories, Inc.'s Life Science business segment. Additionally, the contract research organizations segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing outsourcing trends in biopharmaceutical research and development, increasing demand for specialized viral inactivation services, and cost-effective solutions offered by contract research organizations.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of established biopharmaceutical companies, robust healthcare infrastructure, and stringent regulatory standards promoting the adoption of advanced viral inactivation technologies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding biopharmaceutical sector, increasing investments in healthcare infrastructure, and growing emphasis on research and development activities in emerging economies. For instance, HPG Co., Ltd. created a highly concentrated catechin EGCg (Epigallocatechin Gallate) formulation technique in February 2022, which is soluble in water and has outstanding stability during storage. In order to stable the product at a high concentration in an aqueous solution, the company has also begun the process of filing a patent application. It has an effect that makes some components of the influenza virus inactive.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Viral clearance processes are now more effective, efficient, and scalable thanks to ongoing developments in viral inactivation technologies, including the creation of new chemical agents, cutting-edge filtration techniques, and sophisticated irradiation methods. Through the provision of safer, more affordable, and more dependable viral inactivation solutions to biopharmaceutical manufacturers, these technological advancements propel market expansion. For instance, in January 2024, Merck KGaA declared that it had completed the acquisition of Amnis Therapeutics, a biopharmaceutical company in the clinical stage that specializes in creating innovative treatments for autoimmune disorders.
By the method, the solvent/detergent inactivation segment accounted for the highest revenue-grossing segment in the global viral inactivation market in 2023 owing to the increasing demand for plasma-derived products and blood safety measures, stringent regulatory requirements, and proven efficacy in viral clearance. For instance, in February 2023, Charles River Laboratories International, Inc. announced the expansion of its viral clearance and safety testing services by establishing a new facility in Shanghai, China, to meet the growing demand for biologics development in the Asia-Pacific region. Additionally, the other methods segment is predicted to grow at the fastest CAGR during the forecast period owing to the development of novel viral inactivation technologies, increasing focus on enhancing biopharmaceutical manufacturing efficiency, and rising investments in research and development for advanced viral clearance solutions.
By product, the kits and reagents segment accounted for the highest revenue-grossing segment in the global viral inactivation market in 2023 owing to the growing demand for ready-to-use solutions, expanding biopharmaceutical manufacturing activities, and the convenience offered by pre-packaged viral inactivation kits and reagents. For instance, Parker Hannifin Corporation unveiled a new range of viral filtration products in November 2023 with the goal of improving the effectiveness and security of biopharmaceutical manufacturing procedures. Additionally, the viral inactivation systems and accessories segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of automated viral clearance processes, advancements in system integration and compatibility, and the need for scalable solutions in biopharmaceutical manufacturing.
By application, the vaccines and therapeutics segment accounted for the highest revenue-grossing segment in the global viral inactivation market in 2023 owing to the growing demand for safe and effective vaccines, expanding therapeutic development pipelines, and stringent regulatory requirements for viral safety in biopharmaceutical products. For instance, Thermo Fisher Scientific developed the non-hazardous InhibiSURE Viral Inactivation Medium formula in March 2022. a novel viral transport medium that stabilizes viral RNA for use in in vitro diagnostic testing techniques and facilitates the rapid transfer and inactivation of the SARS-CoV-2 virus. Additionally, the cellular and gene therapy products segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing investments in regenerative medicine, advancements in cellular and gene therapy research, and rising adoption of viral inactivation technologies to ensure product safety and efficacy.
By end-user, the pharmaceutical and biotechnology companies segment accounted for the highest revenue-grossing segment in the global viral inactivation market in 2023 owing to the expanding biopharmaceutical pipelines, stringent regulatory compliance requirements, and increasing outsourcing of viral clearance processes by pharmaceutical and biotechnology firms. For instance, Danaher Corporation expanded its portfolio of life sciences and diagnostics solutions in October 2023 when it completed the acquisition of Bio-Rad Laboratories, Inc.'s Life Science business segment. Additionally, the contract research organizations segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing outsourcing trends in biopharmaceutical research and development, increasing demand for specialized viral inactivation services, and cost-effective solutions offered by contract research organizations.
North American region is anticipated to have the highest revenue share during the forecast period owing to the presence of established biopharmaceutical companies, robust healthcare infrastructure, and stringent regulatory standards promoting the adoption of advanced viral inactivation technologies. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding biopharmaceutical sector, increasing investments in healthcare infrastructure, and growing emphasis on research and development activities in emerging economies. For instance, HPG Co., Ltd. created a highly concentrated catechin EGCg (Epigallocatechin Gallate) formulation technique in February 2022, which is soluble in water and has outstanding stability during storage. In order to stable the product at a high concentration in an aqueous solution, the company has also begun the process of filing a patent application. It has an effect that makes some components of the influenza virus inactive.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Method, Product, Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Viral Inactivation Market Report 2023 - 2034
Viral Inactivation Market Analysis & Forecast by Method 2023 - 2034 (Revenue USD Bn)
- Solvent Detergent Method
- pH Adjustment Method
- Pasteurization
- Others
Viral Inactivation Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Viral Inactivation Systems and Accessories
- Kits and Reagents
- Others
Viral Inactivation Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Vaccines and Therapeutics
- Blood & Blood Products
- Cellular & Gene Therapy Products
- Others
Viral Inactivation Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Pharmaceutical and Biotechnology Companies
- Contract Research Organisations
- Others
Viral Inactivation Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Viral Inactivation Market: Method Estimates & Trend Analysis
8. Viral Inactivation Market: Product Estimates & Trend Analysis
9. Viral Inactivation Market: Application Estimates & Trend Analysis
10. Viral Inactivation Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Viral Inactivation Market
13. Europe Global Viral Inactivation Market
14. Asia Pacific Global Viral Inactivation Market
15. Latin America Global Viral Inactivation Market
16. MEA Global Viral Inactivation Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Merck KGaA
- Charles River Laboratories International Inc.
- Sartorius AG
- Parker Hannifin Corporation
- Danaher Corporation
- Texcell Inc.
- Clean Cells
- GE Healthcare Life Sciences
- Cerus Corporation
- Lonza Group AG
- MacoPharma SA
- ViruSure GmbH
- SGS SA
- WuXi AppTec
- BioReliance Corporation.
